Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00861107 · ClinicalTrials.gov registry record · Phase 1
In-Situ Therapeutic Cancer Vaccine for Metastatic Cancer Combining AlloStim With Tumor Cryoablation
A Phase 1 study, sponsored by Mirror Biologics.
- Completed
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
NCT00861107: Completed Phase 1 study, sponsored by Mirror Biologics.
NCT00861107 is a Phase 1 study that has completed, run by Mirror Biologics. The registered enrollment target is 50 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (17% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00861107, a Phase 1 study, has completed, sponsored by Mirror Biologics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
This is a Phase I/II study to investigate the feasibility of creating a personalized therapeutic cancer vaccine within the body. A vaccine contains a source of tumor antigen and an adjuvant. In this study, tumor antigen is generated by freezing a tumor by a minimally invasive percutaneous (through the skin) cryoablation procedure. The study drug, AlloStim, is injected into the ablated tumor to promote development of an anti-tumor immune response.
Interventions
- BIOLOGICAL AlloStim-7
- PROCEDURE percutaneous tumor cryoablation
- BIOLOGICAL AlloStim8 or AlloStim-9
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2009-08 |
| Est. Completion | 2011-05 |
| Phase | Phase 1 |
What the finished NCT00861107 record still lists
NCT00861107 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (17% lower).
The record links to 0 conditions, and to 3 interventions - of which AlloStim-7 is the first listed.
NCT00861107 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00861107 about?
NCT00861107 is a clinical study titled "In-Situ Therapeutic Cancer Vaccine for Metastatic Cancer Combining AlloStim With Tumor Cryoablation". This is a Phase I/II study to investigate the feasibility of creating a personalized therapeutic cancer vaccine within the body. A vaccine contains a source of tumor antigen and an adjuvant. In this study, tumor antigen is generated by freezing a tumor by a minimally invasive percutaneous (through t...
What is the current status of trial NCT00861107?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2009-08. Estimated completion is 2011-05.
What interventions are being tested in trial NCT00861107?
The interventions under investigation include: AlloStim-7 (BIOLOGICAL), percutaneous tumor cryoablation (PROCEDURE), AlloStim8 or AlloStim-9 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00861107?
This trial is sponsored by Mirror Biologics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00861107's enrollment target sits among peer trials
50 973rd of 2000 higher than 984 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia